Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions View by Topic View by Date Must Reads by Date Must reads for theWeek ending July 21, 2019 Transdermal estradiol may modulate the relationship between sleep, cognition, CARMELINA confirms linagliptin’s renal, CV safety, but it’s still third-line for type 2 diabetes, Cathepsin Z identified as a potential biomarker for osteoporosis, More must reads Must reads for theWeek ending July 14, 2019 FDA Warning Letters Fall on Trump’s Watch, Once-weekly teriparatide still achieves bone mineral density gains, Low-fat dairy associated with decreased risk of type 2 diabetes, MedPAC to Congress: End “Incident-To” Billing, Cost of Physician Burnout Estimated at $4.6 Billion a Year, More must readsMust reads for theWeek ending July 7, 2019 Subclinical Hypothyroidism Not Helped by Levothyroxine, Mortality caused by chronic liver disease in setting of diabetes continues to rise, CAROLINA findings reaffirm linagliptin’s safety, free glimepiride of CV-risk stigma, More must readsMust reads for theWeek ending June 30, 2019 Specific prednisone regimen safer than others when used with abiraterone for mCR prostate cancer, Surprise! High-fat dairy may protect against metabolic syndrome, Surprise billing legislation passes Senate committee, Do Black Patients with Type 2 Diabetes Gain Cardiac Benefit From SGLT2 and GLP-1 Drugs?, Study: Medicare may best Medicare Advantage at reducing readmissions, More must readsMust reads for theWeek ending June 23, 2019 Program Meets Social Needs of 90% of Patients, Opioid Retail Prescriptions Declined 33% Over 5 Years, Sharing Notes With Patients Improves Medication Comprehension, Benefits of Medicare Shared Savings Program ACOs lacking, Genetic analysis links PCSK9 inhibition and CV mortality, More must readsPages« first 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 last »
